The Children's Tumor Foundation Is Revolutionizing the Field of NF Research
Traditionally, medical research has been based on a culture of competition between scientists, who were pitted against one another to discover cures and treatments. This model led to data stockpiling, a process that ultimately delayed the drug discovery process.
Frustrated by this traditional model of drug research and driven by our belief in a culture of collaboration, the Children's Tumor Foundation formulated a strategic plan to accelerate the cure for neurofibromatosis by actively engaging all stakeholders in NF research: patients, scientists, doctors, pharmaceutical companies and the biotechnology field.
In a few short years, we have grown from a foundation that funds promising science to one that catalyzes the drug discovery process through a series of innovative processes, key partnerships and strategic investments.
The Children’s Tumor Foundation is so much more than a funder of scientific research. We have revolutionized the field of NF research, forging new pathways for one reason and one reason only: to benefit the millions of people living with NF.
Our Most Recent Achievements
Click hereto see a clear view of the following brochure.
Disease Maps Illustrate Research Funding
The Foundation, in collaboration with Thomson Reuters, has generated interactive disease maps to illustrate the Foundation’s research processes and investments. Thomson Reuters created disease schemas for neurofibromatosis types 1 and 2 and schwannomatosis in order to enable the mapping of project management and finance data on the disease pathways involved in each of the disorders.
These pathway maps give a snapshot of the different processes involved in each disorder. By clicking on the dollar signs, the list of grants funded by the Foundation can be seen. By moving from disease schema to dashboard, funding in the different aspects of the research and development process can be seen. The schemas can be easily adjusted and/or converted to other formats.
The disease maps will be updated on a yearly basis in collaboration with Thomson Reuters.